Joan W. Chen

Joan W. Chen

Auto-generated profile, based on publicly available information

Joan W. Chen

Rancho BioSciences, San Diego, 92127 California, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
EOElizabeth M O'DAy
Elizabeth M O'DAy
GIGreg E Idos
Greg E Idos
CHCollin Hill
Collin Hill
JCJoan W Chen
Joan W Chen
GWGerhard Wagner
Gerhard Wagner
Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells Elizabeth M O’Day,1,2 Greg E Idos,3 Collin Hill,4 Joan W Chen,5 Gerhard Wagner1 1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; 2Olaris Therapeutics, Cambridge, MA 02138, USA; 3Division of Gastroenterology and Liver Disease, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA; 4PerkinElmer, Waltham, MA 02451, USA; 5Rancho Biosciences, San Diego, CA 92127, USA Background: Cancer cells have altered bioenergetics, which contributes to their ability to proliferate, survive in unusual microenvironments, and invade other tissues. Changes in glucose metabolism can have pleomorphic effects on tumor cells. Methods: To investigate potential mechanisms responsible for the increased malignancy associated with altered glucose metabolism, we used an unbiased nuclear magnetic resonance spectroscopy screening method to identify glucose metabolites differentially produced in a highly malignant human triple-negative breast cancer (TNBC) cell line (BPLER) and a less malignant isogenic TNBC cell line (HMLER). Results: N-acetylneuraminic acid (Neu5Ac), the predominant sialic acid derivative in mammalian cells, which forms the terminal sugar on mucinous cell surface glycoproteins, was the major glucose metabolite that differed. Neu5Ac was ~7-fold more abundant in BPLER than HMLER. Loss of Neu5Ac by enzymatic removal or siRNA knockdown of cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS), which activates cellular sialic acids for glycoprotein conjugation, had no significant effect on cell proliferation, but decreased the ability of BPLER to invade through a basement membrane. Conversely, overexpressing CMAS in HMLER increased invasivity. TNBCs in The Cancer Genome Atlas also had significantly more CMAS copy number variations and higher mRNA expression than non-TNBC, which have a better prognosis. CMAS knockdown in BPLER ex vivo blocked xenograft formation in mice. Conclusion: Neu5Ac is selectively highly enriched in aggressive TNBC, and CMAS, the enzyme required for sialylation, may play an important role in TNBC tumor formation and invasivity. Keywords: triple-negative breast cancer, metabolism, invasion, cytidine monophosphate N-acetylneuraminic acid, sialic acid, NMR spectroscopy, metabolomics

1 July 2018 in Cancer Research
Verified
Journal Article
Closed access
CSCraig R. Stumpf
Craig R. Stumpf
JCJoan Chen
Joan Chen
VGVikas K. Goel
Vikas K. Goel
GPGregory S. Parker
Gregory S. Parker
GCGary G. Chiang
Gary G. Chiang
KWKevin R. Webster
Kevin R. Webster
Mitogen-activated protein (MAP) kinase signaling cascades play a vital role in T-cell activation upon antigen recognition. MNK1 and MNK2 are important downstream effector kinases in the MAPK pathway that largely function in regulating the expression of important signaling molecules, including cytokines and immune checkpoint receptors. MNKs are primarily thought to regulate the expression of select mRNAs, predominantly via post-transcriptional mechanisms involving the phosphorylation of the eukaryotic translation initiation factor eIF4E as well as the RNA binding proteins hnRNPA1 and PSF. eFT508 is a potent and highly selective inhibitor of MNK1 and MNK2 that has been shown to promote antitumor immunity by decreasing the expression of immunosuppressive molecules, such as immune checkpoint receptors. In order to identify key T-cell components that are regulated by MNK phosphorylation and may mediate the effects of eFT508 treatment, we performed an unbiased phosphoproteomic analysis of T cells during the early stages of T-cell receptor-mediated stimulation with and without eFT508 treatment. Primary human T cells were pretreated with eFT508 for two hours prior to stimulation with αCD3/αCD28 for an additional 30 minutes. Protein samples were then prepared for multiplexed phosphoproteomic analysis by mass spectrometry. Consistent with previous proteomic studies using stimulated T cells, a number of phosphopeptides associated with T-cell receptor signaling, among other cellular activities, were detected. Moreover, treatment with eFT508 specifically blocked the phosphorylation of distinct phosphosites on select proteins. The phosphoproteins modulated by eFT508 treatment are involved in important T-cell signaling pathways, cell proliferation and differentiation programs, stress responses, and post-transcriptional and translational gene regulation. Furthermore, there was enrichment for specific sequences surrounding the phosphorylation site in eFT508-sensitive peptides, highlighting a potential mechanism mediating MNK target recognition. Confirmation of MNK-mediated phosphorylation of novel substrates is being conducted in vitro by biochemical analysis of direct phosphorylation of potential substrates by MNK1 or MNK2 and in cellular lysates treated with eFT508 by Western blot analysis using phosphosite-specific antibodies. These findings have significantly expanded our understanding of cell signaling through MNK1 and MNK2 and will help to illuminate potential regulatory programs through which inhibition of MNKs by eFT508 can modulate antitumor immunity. Citation Format: Craig R. Stumpf, Joan Chen, Vikas K. Goel, Gregory S. Parker, Gary G. Chiang, Peggy A. Thompson, Kevin R. Webster. Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3855.

14 May 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
LDLucas Delmonico
Lucas Delmonico
SASaid Attiya
Said Attiya
JCJoan W. Chen
Joan W. Chen
JOJohn C. Obenauer
John C. Obenauer
EGEdward C. Goodwin
Edward C. Goodwin
MFMarcia V. Fournier
Marcia V. Fournier
Background. With the development of new drug combinations and targeted treatments for multiple types of cancer, the ability to stratify categories of patient populations and to develop companion diagnostics has become increasingly important. A panel of 325 RNA biomarkers was selected based on cancer-related biological processes of healthy cells and gene expression changes over time during nonmalignant epithelial cell organization. This “cancer in reverse” approach resulted in a panel of biomarkers relevant for at least 7 cancer types, providing gene expression profiles representing key cellular signaling pathways beyond mutations in “driver genes.” Objective. To further investigate this biomarker panel, the objective of the current study is to (1) validate the assay reproducibility for the 325 RNA biomarkers and (2) compare gene expression profiles side by side using two technology platforms. Methods and Results. We have mapped the 325 RNA transcripts and in a custom NanoString nCounter expression panel to be compared to all potential probe sets in the Affymetrix Human Genome U133 Plus 2.0. The experiments were conducted with 10 unique biological formalin-fixed paraffin-embedded (FFPE) breast tumor samples. Each site extracted RNA from four sections of 10-micron thick FFPE tissue over three different days by two different operators using an optimized standard operating procedure and quality control criteria. Samples were analyzed using mas5 in BioConductor and NanoStringNorm in R. Pearson correlation showed reproducibility between sites for all 60 samples with r=0.995 for Affymetrix and r=0.999 for NanoString. Correlation in multiple days and multiple users was for Affymetrix r=0.962−0.999 and for NanoString r=0.982−0.991. Conclusion. The 325 RNA biomarkers showed reproducibility in two technology platforms with moderate to high concordance. Future directions include performing clinical validation studies and generating rationale for patient selection in clinical trials using the technically validated assay.